4,676
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody

ORCID Icon, , , , , , , , , , , , , , , & ORCID Icon show all
Pages 1638-1648 | Received 29 May 2021, Accepted 23 Jul 2021, Published online: 18 Aug 2021

Reprints and Permissions

This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.

You are not required to obtain permission to reuse this article in part or whole.